By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lipocine Inc. 

675 Arapeen Drive
Suite 202
Salt Lake City  Utah  84108  U.S.A.
Phone: 801-994-7383 Fax:


Company News
Lipocine Inc. (LPCN) Announces First Subject Dosed In Multi-Dose PK Study For Its Oral Product Candidate For The Prevention Of Pre-Term Birth 9/28/2015 7:53:38 AM
Lipocine Inc. (LPCN) To Present At Ladenburg Thalmann 2015 Healthcare Conference 9/22/2015 8:42:32 AM
Lipocine Inc. (LPCN) Submits New Drug Application To FDA For Its Oral Testosterone Replacement Product Candidate, LPCN 1021 8/31/2015 7:22:51 AM
Lipocine Inc. (LPCN) Announces Financial And Operational Results For The Second Quarter Of 2015 8/11/2015 1:12:56 PM
Lipocine Inc. (LPCN) To Present At 35th Annual Canaccord Genuity Growth Conference 8/5/2015 10:54:58 AM
Lipocine Inc. (LPCN)'s Oral Testosterone Well Tolerated In Phase III Study 6/30/2015 7:14:05 AM
Lipocine Inc. (LPCN) To Present At The JMP Securities Life Sciences Conference 6/16/2015 10:50:48 AM
Lipocine Inc. (LPCN) Announces Successful Completion Of Food Effect Study For LPCN 1021, An Oral Testosterone Product Candidate 6/15/2015 9:01:11 AM
Lipocine Inc. (LPCN) Announces Development Plans For LPCN 1107 6/8/2015 7:51:37 AM
Lipocine Inc. (LPCN) Receives FDA Orphan Drug Designation For LPCN 1107, An Oral Product Candidate For The Prevention Of Preterm Birth 6/2/2015 1:28:07 PM